Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs.
The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.
The company’s lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials for the treatment of non-small cell lung cancer and small cell lung cancer.
It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreas; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2009 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ryan Confer |
Contact Details
Address: 3300 Bee Cave Road, Suite 650-227 Austin, Texas 78746 United States | |
| Phone | 877-774-4679 |
| Website | genprex.com |
Stock Details
| Ticker Symbol | GNPX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595248 |
| CUSIP Number | 372446104 |
| ISIN Number | US3724462037 |
| Employer ID | 90-0772347 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan M. Confer M.S. | President, Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| David M. Schloss | Senior Vice President of Human Resources |
| Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property and Licensing |
| Dr. Suzanne Thornton-Jones Ph.D. | Senior Vice President of Regulatory Affairs and Quality |
| Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific and Medical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 1, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 23, 2025 | 8-K | Current Report |